I-O company launches with vaccine and immunotherapy platform

28 March 2019

Immuno-oncology (I-O) company Elicio Therapeutics has launched with a $30 million financing to treat a range of cancers with a new vaccine and immunotherapy platform.

The US company will develop precision vaccines, immune-stimulators and cellular therapies based on the work of Darrell Irvine from Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.

Elicio claims that its Amphiphile platform is the first that enables precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body’s own system of immune defences, with the aim of achieving durable cures.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK